REGENERON PHARMACEUTICALS, INC.
About REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.3B
- Net income
- $4.5B
- Total assets
- $40.6B
- Market cap
- $66.6B
- Operating margin
- 24.9%
- Net margin
- 31.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.3B
- Operating expenses
- $10.8B
- Operating income
- $3.6B
- Income tax
- $725.8M
- Net income
- $4.5B
- EPS (basic)
- $43.07
- EPS (diluted)
- $41.48
Balance sheet
- Total assets
- $40.6B
- Current assets
- $18.0B
- Total liabilities
- $9.3B
- Current liabilities
- $4.4B
- Shareholders’ equity
- $31.3B
Cash flow
- Operating cash flow
- $5.0B
- Investing cash flow
- -$629.1M
- Financing cash flow
- -$3.7B
- Net cash flow
- $634.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $66.6B
- P/E ratio
- 14.7
- EPS (diluted)
- $41.48
- Dividend yield
- 0.62%
- Shares outstanding
- 109.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 2, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $4.5B in FY2025.
- Revenue declined 11% from FY2021 to FY2025.
- Trading 25% below its 52-week high.
- Pays a dividend yielding about 0.62% annually.
- Valued at a price-to-earnings (P/E) ratio of 14.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review REGENERON PHARMACEUTICALS, INC..
Write a review
News about REGENERON PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
